These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 33896567)

  • 21. Does c-Met remain a rational target for therapy in patients with EGFR TKI-resistant non-small cell lung cancer?
    Wu YL; Soo RA; Locatelli G; Stammberger U; Scagliotti G; Park K
    Cancer Treat Rev; 2017 Dec; 61():70-81. PubMed ID: 29121501
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Precision medicine approaches to lung adenocarcinoma with concomitant MET and HER2 amplification.
    Oh DY; Jung K; Song JY; Kim S; Shin S; Kwon YJ; Oh E; Park WY; Song SY; Choi YL
    BMC Cancer; 2017 Aug; 17(1):535. PubMed ID: 28806950
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Second-generation inhibitors of Bruton tyrosine kinase.
    Wu J; Liu C; Tsui ST; Liu D
    J Hematol Oncol; 2016 Sep; 9(1):80. PubMed ID: 27590878
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis.
    Awad MM; Leonardi GC; Kravets S; Dahlberg SE; Drilon A; Noonan SA; Camidge DR; Ou SI; Costa DB; Gadgeel SM; Steuer CE; Forde PM; Zhu VW; Fukuda Y; Clark JW; Jänne PA; Mok T; Sholl LM; Heist RS
    Lung Cancer; 2019 Jul; 133():96-102. PubMed ID: 31200835
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression.
    Chen RL; Zhao J; Zhang XC; Lou NN; Chen HJ; Yang X; Su J; Xie Z; Zhou Q; Tu HY; Zhong WZ; Yan HH; Guo WB; Wu YL; Yang JJ
    BMC Cancer; 2018 Nov; 18(1):1171. PubMed ID: 30477470
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable.
    Reungwetwattana T; Liang Y; Zhu V; Ou SI
    Lung Cancer; 2017 Jan; 103():27-37. PubMed ID: 28024693
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dabrafenib Active in Rare NSCLC Subtype.
    Cancer Discov; 2016 Jul; 6(7):OF4. PubMed ID: 27207893
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting c-MET in the battle against advanced nonsmall-cell lung cancer.
    Landi L; Minuti G; D'Incecco A; Cappuzzo F
    Curr Opin Oncol; 2013 Mar; 25(2):130-6. PubMed ID: 23385860
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping.
    Heist RS; Sequist LV; Borger D; Gainor JF; Arellano RS; Le LP; Dias-Santagata D; Clark JW; Engelman JA; Shaw AT; Iafrate AJ
    J Thorac Oncol; 2016 Aug; 11(8):1242-1245. PubMed ID: 27343442
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Interest of crizotinib in a lung cancer patient with de novo amplification of MET].
    Rabeau A; Rouquette I; Vantelon JM; Taranchon-Clermont E; Mazières J
    Rev Mal Respir; 2017 Jan; 34(1):57-60. PubMed ID: 27745897
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The c-Met inhibitors: a new class of drugs in the battle against advanced nonsmall-cell lung cancer.
    Sgambato A; Casaluce F; Maione P; Rossi A; Rossi E; Napolitano A; Palazzolo G; Bareschino MA; Schettino C; Sacco PC; Ciardiello F; Gridelli C
    Curr Pharm Des; 2012; 18(37):6155-68. PubMed ID: 22873759
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Successful Treatment of a Patient With NSCLC Harboring an EGFR Mutation and a Concomitant Met Exon 14 Skipping Mutation Combining Afatinib and Crizotinib.
    Kauffmann-Guerrero D; Kahnert K; Kumbrink J; Syunyaeva Z; Tufman A; Huber RM
    Clin Lung Cancer; 2019 Jan; 20(1):59-62. PubMed ID: 30341016
    [No Abstract]   [Full Text] [Related]  

  • 33. ALK inhibitors in lung cancer.
    Heath E
    Clin Adv Hematol Oncol; 2009 Oct; 7(10):649-50. PubMed ID: 20040904
    [No Abstract]   [Full Text] [Related]  

  • 34. Targeted kinase inhibitors in lung cancer: from EGFR to patients.
    Apolone G; La Vecchia C; Garattini S
    Eur J Cancer; 2006 Jan; 42(2):124-5. PubMed ID: 16324837
    [No Abstract]   [Full Text] [Related]  

  • 35. Progress on treatment of MET signaling pathway in non-small cell lung cancer.
    Yu X; Yu S; Fan Y
    Int J Clin Oncol; 2020 Aug; 25(8):1450-1458. PubMed ID: 32440811
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MET receptor juxtamembrane exon 14 alternative spliced variant: novel cancer genomic predictive biomarker.
    Ma PC
    Cancer Discov; 2015 Aug; 5(8):802-5. PubMed ID: 26243862
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting MET amplification in EGFR-mutant non-small-cell lung cancer.
    Rosell R; Chaib I; Santarpia M
    Lancet Respir Med; 2020 Nov; 8(11):1068-1070. PubMed ID: 32479793
    [No Abstract]   [Full Text] [Related]  

  • 38. Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling.
    Le X; Freed JA; VanderLaan PA; Huberman MS; Rangachari D; Jorge SE; Lucena-Araujo AR; Kobayashi SS; Balasubramanian S; He J; Chudnovsky Y; Miller VA; Ali SM; Costa DB
    Clin Lung Cancer; 2015 Sep; 16(5):e105-9. PubMed ID: 25922291
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of phosphoinositide 3-kinase pathway inhibitors in the treatment of lung cancer.
    Engelman JA
    Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4637-40. PubMed ID: 17671156
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Responses to crizotinib can occur in c-MET overexpressing nonsmall cell lung cancer after developing EGFR-TKI resistance.
    Xu Y; Fan Y
    Cancer Biol Ther; 2019; 20(2):145-149. PubMed ID: 30422759
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.